Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs

Kidney International

Volumn 84, Issue 3, 2013, Pages 578-584

  Kleophas, Werner ^a,b   Karaboyas, Angelo ^c   Li, Yun ^c,d   Bommer, Juergen ^e   Reichel, Helmut ^f   Walter, Andreas ^g   Icks, Andrea ^h   Rump, Lars C ^b   Pisoni, Ronald L ^c   Robinson, Bruce M ^c,d   Port, Friedrich K ^c,d  

^a Gemeinschaftspraxis Karlstrasse   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e Dialysezentrum Heidelberg   (Germany)

^f Hochsch F Technik und Wirtschaft   (Germany)

^g National Association of Statutory Health Insurance Physicians   (Germany)

^h Department of Orthopedic Surgery   (Germany)

Author keywords

dialysis; DOPPS; flat rate; quality assurance system; reimbursement

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; IRON;

ADULT; AGED; ANEMIA; ARTICLE; COHORT ANALYSIS; COMORBIDITY; COST CONTROL; DATA ANALYSIS; DEMOGRAPHY; FEMALE; GERMANY; HEALTH CARE COST; HEALTH CARE QUALITY; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REIMBURSEMENT; STATISTICAL ANALYSIS; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COST CONTROL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; GERMANY; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; REIMBURSEMENT MECHANISMS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84883455922     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.143     Document Type: Article

References (22)

1. Kleophas W, Reichel H. International study of health care organization and financing: Development of renal replacement therapy in Germany. Int J Health Care Finance Econ 2007; 7: 185-200.
2. Federal Joint Committee, Germany (G-BA)Available at. http://www.english. g-ba.de/.
3. Singh AK, Szczech LA, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
4. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191.
5. Drü eke TB, Locatelli F, Clyne N et al. Normalization of haemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
6. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low haematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
7. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
8. Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 2007; 18: 975-984.
9. Kapoian T, O'Mara NB, Singh AK et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19: 372-379.
10. Charra B, Calemard E, Ruffet M et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286-1291.
11. National Kidney Foundation. K/DOQI clinical practice guidelines for hemodialysis adequacy, 2000. Am J Kidney Dis 2001; 37: S7-S64.
12. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 2001; 37: S182-S238.
13. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S1-S146.
14. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: Hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. Am J Kidney Dis 2006; 48: S1-S322.
15. Locatelli F, Nissenson AR, Barrett BJ et al. Clinical practice guidelines for anemia in chronic kidney disease: Problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2008; 74: 1237-1240.
16. Locatelli F, Pisoni RL, Combe C et al. Anemia in haemodialysis patients of five European Countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132.
17. Saran R, Bragg-Gresham JL, Wizemann V et al. Longer treatment time and slower ultrafiltration in hemodialysis: Associations with reduced mortality in the DOPPS. Kidney Int 2006; 69: 1222-1228.
18. Macdougall IC, Eckardt KU, Locatelli F. Latest US KDOQI Anaemia Guidelines update-what are the implications for Europe? Nephrol Dial Transplant 2007; 22: 2738-2742.
19. Robinson B, Fuller D, Zinsser D et al. The DOPPS Practice Monitor: Rationale and methods for an initiative to monitor the new U.S. bundled dialysis payment system. Am J Kidney Dis 2011; 57: 822-831.
20. Fuller DS, Pisoni RL, Bieber BA et al. The DOPPS Practice Monitor for US dialysis care: Trends through December 2011. Am J Kidney Dis 2012; 61: 342-346.
21. Young EW, Goodkin DA, Mapes DL et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study. Kidney Int 2000; 57: S74-S81.
22. Pisoni RL, Gillespie BW, Dickinson DM et al. The Dialysis Outcomes and Practice Pattern Study (DOPPS): Design, data elements, and methodology. Am J Kidney Dis 2004; 44: 7-15.